ATNM:NYE-Actinium Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 7.83

Change

0.00 (0.00)%

Market Cap

USD 0.17B

Volume

0.76M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York. Address: 275 Madison Avenue, New York, NY, United States, 10016

Company Website : http://www.actiniumpharma.com

Address : 275 Madison Avenue, New York, NY, United States, 10016

Employees : 32

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.03

52 Week High : 13.18

Short Ratio : 5.20

52 Week Low : 5.70

Shorted Shares : 834,676

200 Day Moving Average : 7.46

Shorted Shares Previous Month : 989,863

50 Day Moving Average : 6.39

Shares Held By Insiders : 1.45%

Short Percentage : 4.00%

Shares Held by Institutions : 16.47%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

N/A

 USD232.81B 33.36 3.82
BHVN Biohaven Pharmaceutical Holdin..

N/A

 USD8.83B N/A N/A
RCUS Arcus Biosciences Inc

N/A

 USD2.36B N/A N/A
ADCT ADC Therapeutics SA

N/A

 USD2.26B -99,999.99 N/A
MYOV Myovant Sciences Ltd

N/A

 USD2.10B N/A N/A
ZYME Zymeworks Inc

N/A

 USD1.67B 300.20 N/A
RFL Rafael Holdings Inc

N/A

 USD0.75B N/A N/A
BTX Brooklyn ImmunoTherapeutics In..

N/A

 USD0.62B 2.32 N/A
AMAM Ambrx Biopharma Inc.

N/A

 USD0.58B N/A N/A
CVM CEL-SCI Corporation

N/A

 USD0.52B N/A N/A

ETFs Containing ATNM

Symbol Name Weight Mer Price(Change) Market Cap
RJZ ELEMENTS Linked to the Ro.. 0.00 % 0.75 %

N/A

 USD5.61M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.38% 43% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.38% 43% F 25% F
Trailing 12 Months  
Capital Gain -24.20% 21% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.20% 21% F 6% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 13.68% 43% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.68% 43% F 67% D+
Risk Return Profile  
Volatility (Standard Deviation) 34.58% 75% C 31% F
Risk Adjusted Return 39.56% 46% F 44% F
Market Capitalization 0.17B 47% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.07 82% B- 47% F
Price / Cash Flow Ratio -7.73 57% F 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -33.92% 70% C- 13% F
Return on Invested Capital -65.97% 52% F 2% F
Return on Assets -20.03% 62% D- 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.20 47% F 21% F
Short Percent 3.98% 57% F 44% F
Beta 1.03 64% D 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.